Non-clinical safety assessment of VK4-116 to support human patients afflicted with severe pain disorders.
Ended Awarded Last action
- Contract number
- 75N95019F00089
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,027,022
Award facts
- Opportunity
-
- CRO Support for NCATS In Vitro and In Vivo Toxicology Studies Pre-Solicitation · N01TR172002 · Posted Apr 7, 2020
- CRO Support for NCATS In Vitro and In Vivo Toxicology Studies Award Notice · Posted May 2, 2016
- Contract value 100% obligated
- $1,027,022.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $64,663 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $43,759 | |
| Supplemental Agreement for work within scope | $173,450 | |
| Supplemental Agreement for work within scope | $124,828 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $9,234 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $611,088 |
Show all 12
About this award
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences (NCATS) awarded a $1,027,022.00 cost-plus-fixed-fee delivery order contract to Sri International, a non-profit research institute, for non-clinical safety assessment of the drug candidate VK4-116 to support the treatment of severe pain disorders in human patients. This contract is part of the NCATS "CRO Support for NCATS In Vitro and In Vivo Toxicology Studies" indefinite delivery vehicle (IDV). Sri International has subcontracted a portion of the work to Nova Research Laboratories LLC, a small disadvantaged business, to conduct a GLP hERG assay. The contract does not utilize any set-aside provisions and has a completion date of November 30, 2023.
Quick answers
Who was awarded contract 75N95019F00089?
75N95019F00089 was awarded to Sri International by National Institute on Drug Abuse (National Institutes of Health) on August 1, 2019.
How much is contract 75N95019F00089 worth?
The government has obligated $1,027,022 on 75N95019F00089.
Which agency awarded contract 75N95019F00089?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019F00089, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N95019F00089 an order under another contract?
Yes. 75N95019F00089 is a delivery order under HHSN271201700014I, an indefinite delivery contract, on CRO Support for NCATS In Vitro and In Vivo Toxicology Studies.
Was contract 75N95019F00089 competed?
The extent of competition for 75N95019F00089 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award